[Impact of octreotide on pancreatic fistula after pancreaticoduodenectomy: a prospective study]

What Was Tested

This randomized controlled trial paper looks at Octreotide in the context of pancreatitis (after the acute phase).

To investigate the effect of utilizing octreotide during perioperative period on pancreatic fistula after pancreaticoduodenectomy (PD).

Who Took Part

Three hundreds and six patients admitted from January 2010 to October 2014, who prepared to undergo pancreaticoduodenectomy (PD) were randomly divided into octreotide group (147 cases) and control group (159 cases).

In octreotide group, octreotide was used in subcutaneous injection instantly after PD, each 8 hours until postoperative 10(th) day, and patients in control group were injected with the same volume of saline.

How the Study Was Run

The design is described as randomized.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Differences of pancreatic fistula (Grade A, Grade B, Grade C), hospitalization days and treatment cost were compared. χ(2) test, t-test and Fisher exact test were used to analyzed to the data, respectively.

What Was Measured

The subject headings attached to it are Anastomosis, Surgical, Incidence, Octreotide, Pancreas, Pancreatectomy, Pancreatic Ducts and Pancreatic Fistula.

What This Means in Plain Language

The paper is a randomized study of Octreotide in people with pancreatitis (after the acute phase).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Zhonghua wai ke za zhi [Chinese journal of surgery]), a journal based in China.

More context: the Octreotide compound page, Pancreatitis (after the acute phase) research.